Besifloxacin clinical trials
Also written Besivance, ISV-403 and BOL-303224.
How each study uses besifloxacin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 28 May 2009 · BESIVANCE · NDA 022308 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2009 (4)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 3 |
| 2013 | 2 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 5
Bausch & Lomb Incorporated (11) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Frank A. Bucci, Jr., M.D. (1) · Johns Hopkins University (1) · John, George, M.D. (1) · Ophthalmology Consultants, Ltd. (1) · Cornea Consultants Of Nashville (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses besifloxacin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Besifloxacin in Bacterial KeratitisCompletedNot applicableMcGill University Health Centre/Research Institute of the McGill University Health CentreNCT02497365Written as BesifloxacinHow we know
- Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing PhacoemulsificationCompletedPhase 4Frank A. Bucci, Jr., M.D.NCT01296191Written as besifloxacinHow we know
- Study of Ocular Penetration of Topically Administered FluoroquinolonesCompletedPhase 4Johns Hopkins UniversityNCT00924729Written as Besifloxacin 0.6% ophthalmic suspensionHow we know
- A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.TerminatedPhase 2Cornea Consultants Of NashvilleNCT01928693Written as Besivance 0.6% Ophthalmic SuspensionHow we know
- A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial ConjunctivitisCompletedPhase 3Bausch & Lomb IncorporatedNCT00348348Written as BesifloxacinHow we know
- Clinical and Microbial Efficacy of ISV403 in Bacterial ConjunctivitisCompletedPhase 2Bausch & Lomb IncorporatedNCT00622908Written as ISV-403How we know
- A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.CompletedPhase 3Bausch & Lomb IncorporatedNCT00347932Written as ISV-403How we know
- Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial ConjunctivitisTerminatedPhase 3Bausch & Lomb IncorporatedNCT01740388Written as BesifloxacinHow we know
- Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial ConjunctivitisTerminatedPhase 3Bausch & Lomb IncorporatedNCT01330355Written as BesivanceHow we know
- Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute BlepharitisCompletedPhase 4John, George, M.D.NCT01478256Written as BesifloxocinHow we know
- Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to VehicleCompletedPhase 3Bausch & Lomb IncorporatedNCT01175590Written as BesivanceHow we know
- Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 DaysCompletedPhase 1Bausch & Lomb IncorporatedNCT01120418Written as Besifloxacin Ophthalmic Suspension 0.6%How we know
- Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial ConjunctivitisCompletedPhase 2/3Bausch & Lomb IncorporatedNCT00972777Written as BesifloxacinHow we know
- Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of SubjectsCompletedPhase 1Bausch & Lomb IncorporatedNCT00824070Written as Besifloxacin hydrochlorideHow we know
- Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical InstillationCompletedPhase 1Bausch & Lomb IncorporatedNCT00905762Written as BesifloxacinHow we know
- Systemic Pharmacokinetics of BOL-303224-ACompletedPhase 1Bausch & Lomb IncorporatedNCT00407589Written as BOL-303224-AHow we know
- 2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract SurgeryCompletedPhase 4Ophthalmology Consultants, Ltd.NCT01455233Written as besivanceHow we know
Codes
What other systems call besifloxacin · ClinicalTrials.gg INT005141
- MeSH (NLM) C522124besifloxacinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) BFE2NBZ7NXBESIFLOXACINConfirmed FDA, NLM, Wikidata
- RxNorm 819911Confirmed FDA, Wikidata
- Wikidata Q3638978BesifloxacinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C83553BesifloxacinOne source FDA
- DrugBank DB06771One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C522124 | besifloxacin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | BFE2NBZ7NX | BESIFLOXACIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 819911 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3638978 | Besifloxacin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C83553 | Besifloxacin | One source FDA |
| DrugBank | DB06771 | — | One source Wikidata |
Also registered as besifloxacin hydrochloride (UNII 7506A6J57T).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.